Brainstorm Cell Therapeutics (NASDAQ: BCLI) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Brainstorm Cell Therapeutics to similar companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, risk, dividends and earnings.

Institutional & Insider Ownership

13.1% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 24.7% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Brainstorm Cell Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics’ rivals have a beta of 1.54, indicating that their average share price is 54% more volatile than the S&P 500.

Profitability

This table compares Brainstorm Cell Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Brainstorm Cell Therapeutics N/A -76.45% -59.84%
Brainstorm Cell Therapeutics Competitors -4,408.50% -470.69% -41.97%

Valuation & Earnings

This table compares Brainstorm Cell Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Brainstorm Cell Therapeutics N/A -$4.98 million -11.16
Brainstorm Cell Therapeutics Competitors $217.40 million -$39.40 million -64.85

Brainstorm Cell Therapeutics’ rivals have higher revenue, but lower earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Brainstorm Cell Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics 0 0 1 0 3.00
Brainstorm Cell Therapeutics Competitors 665 2523 6742 134 2.63

Brainstorm Cell Therapeutics presently has a consensus target price of $9.00, indicating a potential upside of 152.10%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.68%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Brainstorm Cell Therapeutics is more favorable than its rivals.

Summary

Brainstorm Cell Therapeutics beats its rivals on 9 of the 13 factors compared.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.